15992-83-3|1,8-Naphthyridin-2-amine| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 15992-83-3 ] Purity: 97% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 15992-83-3 ]

CAS No. :	15992-83-3
Formula :	C₈H₇N₃
M.W :	145.16
SMILES Code :	NC1=NC2=NC=CC=C2C=C1
MDL No. :	MFCD01250851
Boiling Point :	No data available
InChI Key :	CRADWWWVIYEAFR-UHFFFAOYSA-N
Pubchem ID :	4173048

Safety of [ 15992-83-3 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H332-H335
Precautionary Statements:	P261-P280-P305+P351+P338

Computational Chemistry of [ 15992-83-3 ] Show Less

Physicochemical Properties

Num. heavy atoms	11
Num. arom. heavy atoms	10
Fraction Csp3	0.0
Num. rotatable bonds	0
Num. H-bond acceptors	2.0
Num. H-bond donors	1.0
Molar Refractivity	43.94
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	51.8 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	1.13
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	1.11
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	1.22
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	1.07
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	1.26
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	1.16

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-2.11
Solubility	1.12 mg/ml ; 0.00773 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-1.79
Solubility	2.35 mg/ml ; 0.0162 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-2.95
Solubility	0.164 mg/ml ; 0.00113 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	Yes
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-6.4 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	1.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.47

Application In Synthesis of [ 15992-83-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 15992-83-3 ]

[ 15992-83-3 ] Synthesis Path-Downstream 1~35

1
[ 254-60-4 ]
[ 15992-83-3 ]

Yield	Reaction Conditions	Operation in experiment
	With ammonia; potassium amide; at -40℃; for 3h;	A. A solution of [1,8]naphthyridine (0.2 mmol) and potassium amide (0.8 mmol) in liquid ammonia (20 mL) is stirred at -40 C. for 3 h. The solution is concentrated. Residue is partitioned between EtOAc and water. EtOAc layer is separated and washed successively with water and brine. EtOAc layer is dried over sodium sulfate, filtered and concentrated to give [1,8]naphthyridin-2-ylamine which is used as is for the next step.

References: [1]Journal of Organic Chemistry,1981,vol. 46,p. 2134 - 2137.
[2]Patent: US2006/116368,2006,A1 .Location in patent: Page/Page column 49; 50.

2
[ 67-68-5 ]
[ 15992-83-3 ]
[ 152562-93-1 ]

References: [1]Liebigs Annalen der Chemie,1993,p. 471 - 476.

3
2-nitro-1,8-naphthyridine [ No CAS ]
[ 15992-83-3 ]

References: [1]Liebigs Annalen der Chemie,1993,p. 471 - 476.

4
[ 15936-10-4 ]
[ 15992-83-3 ]

References: [1]Polish Journal of Chemistry,1981,vol. 55,p. 2429 - 2438.

5
[ 141-86-6 ]
[ 102-52-3 ]
[ 15992-83-3 ]

Yield	Reaction Conditions	Operation in experiment
72%	With phosphoric acid; at 70 - 75℃; for 0.666667h;	In the reaction flask with a stirrer was added 107 g of 2,6-diamino pyridine and 1070 ml phosphoric acid at room temperature was slowly added dropwise 241 g 1,1,3,3-tetramethoxypropane to the resulting solution, dropwise after an oil bath to heat up, control the internal temperature 70-75 C, for 40 minutes. Then the reaction mixture was poured into 5 liters of ice 5M aqueous sodium hydroxide solution, to ensure that pH> 10, the filter cake (200 ml × 2), and the filtrate was washed with methylene chloride and extracted with dichloromethane (300 ml × 2) the combined dichloromethane phases were washed with 100 g of anhydrous sodium sulfate, filtered, and concentrated to dryness, the resultant crude product was purified by column chromatography (packing agent is alumina, eluting with methylene chloride: methanol (v / v ) = 100: 1), to obtain 102 g of a red solid 1,8-naphthyridin-2-amine, yield 72%, HPLC purity 96%.

References: [1]Patent: CN105399739,2016,A .Location in patent: Paragraph 0019; 0020.
[2]Angewandte Chemie - International Edition,2017,vol. 56,p. 3349 - 3353.
Angew. Chem.,2017,vol. 129,p. 3397 - 3401,5.
[3]Journal of Heterocyclic Chemistry,1997,vol. 34,p. 765 - 771.

6
[ 15992-83-3 ]
[ 17157-48-1 ]
imidazo<1,2-a><1,8>naphthyridine [ No CAS ]

References: [1]Journal of Heterocyclic Chemistry,1997,vol. 34,p. 765 - 771.

Yield	Reaction Conditions	Operation in experiment
		EXAMPLE 16 5-Hydroxy-6-(1,8-naphthyridin-2-yl)-7-oxo-2,3,6,7-tetrahydro-1,4-dithiino[2,3-c]pyrrole (8.45 g.) is added, at 0 C, to a suspension of sodium hydride (0.8 g.) in anhydrous dimethylformamide (125 cc.). The reaction mixture is stirred for half an hour at 0 C, and 1-chlorocarbonyl-4-methylpiperazine (8.45 g.) dissolved in anhydrous dimethylformamide (50 cc.) is then added. After stirring for 21/2 hours at 5 C., the reaction mixture is diluted with ice-water (500 cc.). The precipitate which has appeared is filtered off, washed four times with distilled water (total 200 cc.) and twice with diethyl ether (total 50 cc.) and then dissolved in methylene chloride (300 cc.). The organic solution is washed four times with distilled water (total 160 cc.), dried over anhydrous sodium sulphate, treated with decolourising charcoal (0.2 g.) and evaporated. When the residue liquid reaches a volume of 50 cc., boiling acetonitrile (200 cc.) is added. After cooling for 2 hours at 2 C., the crystals which have appeared are filtered off, washed three times with ice-cold acetonitrile (total 15 cc.) and dried under reduced pressure (20 mm. Hg). The crystals thus isolated (8.0 g.) are dissolved in boiling acetonitrile (270 cc.), decolourising charcoal (0.2 g.) is added to the boiling solution and the whole is filtered. After 24 hours at 2 C., the crystals which have appeared are filtered off, washed three times with ice-cold acetonitrile (total 10 cc.) and dried under reduced pressure (20 mm. Hg). 5-(4-Methylpiperazin-1-yl)carbonyloxy-6-(1,8-naphthyridin-2-yl)-7-oxo-2,3,6,7-tetrahydro-1,4-dithiino[2,3-c]pyrrole (5.8 g.), melting at 255 C., is thus obtained. 5-Hydroxy-6-(1,8-naphthyridin-2-yl)-7-oxo-2,3,6,7-tetrahydro-1,4-dithiino[2,3-c]pyrrole employed as starting material can be obtained in the following way: Preparation of 2-amino-1,8-naphthyridine, m.p. 142 C., according to W. W.
		EXAMPLE 11 4-Methylpiperazine (8 g.) is added all at once to a suspension of 2-(1,8-naphthyridin-2-yl)-3-phenoxy-carbonyloxy-isoindolin-1-one (5.6 g.) in acetonitrile (100 cc.). The solution obtained is stirred for 6 hours at a temperature of about 20 C. The reaction mixture is poured into a suspension of ice (100 g.) in methylene chloride (300 cc.). An 8% aqueous solution of sodium bicarbonate (200 cc.) is added to the suspension obtained. The organic phase is decanted and the aqueous phase is extracted with methylene chloride (400 cc.). The combined organic phases are dried over anhydrous potassium carbonate (10 g.) and concentrated to dryness. The oily residue (8 g.) is taken up in refluxing diisopropyl ether (100 cc.). On cooling the solution, crystals are deposited and are filtered off. 3-(4-Methylpiperazin-1-yl)carbonyloxy-2-(1,8-naphthyridin-2-yl)isoindolin-1-one (2.9 g.), which melts at 183 C., is thus obtained. 2-(1,8-Naphthyridin-2-yl)-3-phenoxycarbonyloxy-isoindolin-1-one can be prepared in the following way: Preparation of 2-amino-1,8-naphthyridine, m.p. 141 C., according to W. W.

8
[ 15992-83-3 ]
[ 101478-14-2 ]

References: [1]Canadian Journal of Chemistry,2000,vol. 78,p. 950 - 956.

9
[ 15992-83-3 ]
[ 15936-09-1 ]
[ 5174-89-0 ]

References: [1]Canadian Journal of Chemistry,2000,vol. 78,p. 950 - 956.

10
[ 15992-83-3 ]
2-nitramino-1,8-naphthyridine [ No CAS ]

References: [1]Canadian Journal of Chemistry,2000,vol. 78,p. 950 - 956.

11
[ 2082-59-9 ]
[ 15992-83-3 ]
2-pentanoylamido-1,8-naphthyridine [ No CAS ]

References: [1]Journal of the American Chemical Society,2001,vol. 123,p. 10475 - 10488.

12
[ 15992-83-3 ]
[ 111-36-4 ]
N-butyl-N'-(1,8-naphthyridin-2-yl)urea [ No CAS ]

References: [1]Journal of the American Chemical Society,2001,vol. 123,p. 10475 - 10488.

13
[ 15936-10-4 ]
[ 15992-83-3 ]
bis(1,8-naphthyridin-2-yl)amine [ No CAS ]

References: [1]Journal of the Chinese Chemical Society,2018,vol. 65,p. 122 - 132.
[2]Chemistry - A European Journal,2007,vol. 13,p. 8667 - 8677.

14
[ 152562-93-1 ]
[ 15992-83-3 ]

References: [1]Liebigs Annalen der Chemie,1993,p. 471 - 476.

15
[ 100-09-4 ]
[ 15992-83-3 ]
N-(1,8-naphthyridin-2-yl)-4-methoxybenzamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With 1,1'-carbonyldiimidazole; In propan-1-ol; water;	EXAMPLE 20 The procedure is similar to that described in Example 1, but starting with 4-methoxybenzoic acid (4.55 g), N,N'-carbonyldiimidazole (6.55 g) and <strong>[15992-83-3]2-amino-1,8-naphthyridine</strong> (5.2 g). The product produced by precipitation in water (8.35 g; m.p. 85 C., viscous) is filtered and then dissolved in boiling 1-propanol (50 cc). After 1 hour's cooling at 4 C., the crystallized solid is separated by filtration, washed with 1-propanol (2*5 cc) and dried at 35 C. under reduced pressure (0.067 kPa). N-(1,8-naphthyridin-2-yl)-4-methoxybenzamide (6.9 g) is produced, m.p. 150 C. 2-Amino-1,8-naphthyridine can be prepared according to U.S. Pat. No. 3,948,917.

References: [1]Patent: US4642308,1987,A .

16
[ 85-44-9 ]
[ 15992-83-3 ]
2-(1,8-naphthyridin-2-yl)phthalimide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In N-methyl-acetamide;	Preparation of 2-(1,8-naphthyridin-2-yl)phthalimide (8.6 g.), m.p. 250 C., by reacting <strong>[15992-83-3]2-amino-1,8-naphthyridine</strong> (9.9 g.) with phthalic anhydride (10.2 g.) in dimethylformamide (75 cc.) at 150 C. for 1 hour 30 minutes.

References: [1]Patent: US4016274,1977,A .

17
[ 15992-83-3 ]
[ 10489-75-5 ]
5-hydroxy-6-(1,8-naphthyridin-2-yl)-7-oxo-2,3,6,7-tetrahydro-1,4-dithiino[2,3-c]pyrrole [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In diphenylether; acetic acid;	Preparation of 5,7-dioxo-6-(1,8-naphthyridin-2-yl)-2,3,6,7-tetrahydro-1,4-dithiino[2,3-c]pyrrole (16.0 g.), m.p. 200 C., by reacting <strong>[15992-83-3]2-amino-1,8-naphthyridine</strong> (8.65 g.) with 5,6-dihydro-1,4-dithiine-2,3-dicarboxylic acid anhydride (22.0 g.) [prepared according to the method of H. R. Schweizer, Helv. Chim. Acta, 52, 2229 (1969)] in diphenyl ether (70 cc.) at 150 C. for half an hour, in the presence of anhydrous acetic acid (0.4 cc.). Preparation of 5-hydroxy-6-(1,8-naphthyridin-2-yl)-7-oxo-2,3,6,7-tetrahydro-1,4-dithiino[2,3-c]pyrrole (13.0 g.), m.p. 260 C., by reacting sodium borohydride (2.15 g.) with 5,7-dioxo-6-(1,8-naphthyridin-2-yl)-2,3,6,7-tetrahydro-1,4-dithiino[2,3-c]pyrrole (18.0 g.) in anhydrous tetrahydrofuran (200 cc.) to which anhydrous methanol (80 cc.) has been added gradually, at a temperature not exceeding 40 C.

References: [1]Patent: US3948917,1976,A .

18
[ 626-05-1 ]
[ 15992-83-3 ]
[ 1228096-07-8 ]

References: [1]Dalton Transactions,2010,vol. 39,p. 3890 - 3896.

19
[ 1228095-93-9 ]
[ 15992-83-3 ]
[ 1345416-88-7 ]

References: [1]Dalton Transactions,2010,vol. 39,p. 3890 - 3896.

20
[ 15992-83-3 ]
[ 1408289-75-7 ]

References: [1]Tetrahedron Letters,2012,vol. 53,p. 6544 - 6547,4.

21
[ 15992-83-3 ]
[ 898257-85-7 ]

References: [1]Tetrahedron Letters,2012,vol. 53,p. 6544 - 6547,4.

22
[ 108-24-7 ]
[ 15992-83-3 ]
[ 1569-41-1 ]

References: [1]Tetrahedron Letters,2012,vol. 53,p. 6544 - 6547,4.

23
[ 141-86-6 ]
[ 5436-21-5 ]
[ 15992-83-3 ]

References: [1]Tetrahedron Letters,2012,vol. 53,p. 6544 - 6547,4.

24
[ 18063-02-0 ]
[ 15992-83-3 ]
2,6-difluoro-N-[1,8]naphthyridin-2-ylbenzamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
21%	With 3-dimethylaminoacrolein; In pyridine; dichloromethane; at 20℃; for 0.5h;	Part II- Synthesis of 2,6-Difluoro-N-[1,8]naphthyridin-2-ylbenzamide; [1,8]-Naphthyridin-2-ylamine (85 mg, 0.59 mmol) was dissolved in dichloromethane(2 mL) and pyridine (0.10 mL, 1.2 mmol). 2,6-Difluorobenzoyl chloride (0.068 mL, 0.76mmol) was then added and the reaction mixture was stirred at room temperature for 30 minutes. Next, the reaction mixture was diluted with ethyl acetate and washed with water followed bybrine. The resulting organic solution was purified by column chromatography (EtOAc/hexanes) to give 2,6-difluoro-N-[1,8]naphthyridin-2-ylbenzamide. Yield 35 mg (21 %).LCMS (ESI): calc. C1sH9FzN30 = 285; obs. M+H = 286.

References: [1]Patent: WO2013/169864,2013,A2 .Location in patent: Paragraph 00199.

25
[ 141-86-6 ]
[ 927-63-9 ]
[ 15992-83-3 ]

Yield	Reaction Conditions	Operation in experiment
21%	at 120℃; for 10h;	Part I-- Synthesis of [1,8]-Naphthyridin-2-ylamine; Pyridine-2,6-diamine (0.30 g, 2.8 mmol), 3-dimethylaminoacrolein (90%, 0.30 g, 2.8mmol), and polyphosphoric acid (PPA) (2.7 mL) were combined and the reaction mixture washeated to 120 oc for 10 hours. Then, the reaction mixture was poured on ice water and neutralized with solid sodium carbonate. The resulting aqueous mixture was extracted threetimes with ethyl acetate and the combined organic extracts were washed with brine,concentrated, and purified by column chromatography (EtOAc/hexanes) to give [1,8]naphthyridin-2-ylamine. Yield 85 mg (21 %). LCMS (ESI): calc. C8H7N3 = 145; obs. M+H =146.

References: [1]Patent: WO2013/169864,2013,A2 .Location in patent: Paragraph 00198.

26
[ 15992-83-3 ]
[ 1610978-26-1 ]

References: [1]Journal of Medicinal Chemistry,2014,vol. 57,p. 1063 - 1078.

27
[ 6160-65-2 ]
[ 15992-83-3 ]
C₁₂H₉N₅S [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2014,vol. 57,p. 1063 - 1078.

28
C₂₃H₁₆F₆O₂S₂ [ No CAS ]
[ 15992-83-3 ]
4-(4-(2-(2,5-dimethylthiophen-3-yl)-3,3,4,4,5,5-hexafluorocyclopent-1-en-1-yl)-5-methylthiophen-2-yl)-N-(1,8-naphthyridin-2-yl)benzamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
24%	With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine; In dichloromethane; for 10h;Inert atmosphere;	The synthetic route for diarylethene 1O is shown in Scheme 2 . The intermediate compounds 2 and 3 were synthesized according to the similar procedures as previous descriptions [57,58]. A mixture of compound 3 (0.56g, 1.0mmol), 4 (0.15g, 1.0mmol), EDCI (0.23g, 1.2mmol), HOBT (0.16g, 1.2mmol) and triethylamine (0.41mL, 3.0mmol) in anhydrous CH2Cl2 (50mL) was stirred at room temperature for 10h under a nitrogen atmosphere. The reaction mixture was washed with water, dried over anhydrous Na2SO4, and evaporated. The crude product was purified by column chromatography using petroleum ether/ ethyl acetate (v/v=1:1) as eluent to obtain 0.15g of the target compound 1O as white solid in 24% yield. M.p. 504-505K; 1H NMR (400MHz, THF, ppm): delta 1.82 (s, 3H), 1.89 (s, 3H), 2.32 (s, 3H), 6.71 (s, 1H), 7.27-7.30 (m, 1H), 7.46 (s, 1H), 7.67 (d, 2H, J=8.0Hz), 8.07 (d, 2H, J=8.0Hz), 8.12 (d, 1H, J=8.0Hz), 8.20 (d, 1H, J=8.0Hz), 8.52 (d, 1H, J=8.0Hz), 8.84 (s, 1H), 10.45 (s, 1H); 13C NMR (100MHz, THF, ppm): delta 11.50, 11.62, 12.01, 113.63, 118.49, 118.70, 122.10, 122.44, 122.73, 123.19, 124.37, 126.98, 131.74, 134.40, 134.77, 136.38, 136.93, 138.13, 139.25, 140.62, 151.42, 152.96, 153.39, 163.66; IR (KBr, nu, cm-1):712, 735, 759, 783, 809, 825, 843, 890, 937, 988, 1050, 1102, 1138, 1187, 1264, 1275, 1336, 1424, 1493, 1608, 1674, 2860, 2928, 3217, 3517; Anal. Calcd for C31H21F6N3OS2: C, 59.13; H, 3.36; N, 6.67; found: C, 59.04; H, 3.41; N, 6.59; HRMS-ESI (m/z): [M+Na+]+ calcd. 652.0928, found: 652.0901.

References: [1]Dyes and Pigments,2017,vol. 139,p. 208 - 217.

29
[ 15992-83-3 ]
C₃₁H₂₀F₆N₃OS₂^(1-) [ No CAS ]

References: [1]Dyes and Pigments,2017,vol. 139,p. 208 - 217.

30
1-(2,5-dimethyl-3-thienyl)-2-[2-methyl-5-(4-formylphenyl)-3-thienyl]perfluorocyclopentene [ No CAS ]
C₂₃H₁₆F₆O₂S₂ [ No CAS ]
[ 15992-83-3 ]

References: [1]Dyes and Pigments,2017,vol. 139,p. 208 - 217.

31
[ 30964-00-2 ]
[ 15992-83-3 ]
(E)-7-(4-((2,6-difluoro-4-(6-(3-(pyridin-2-yl)ureido)hex-1-yn-1-yl)phenyl)diazenyl)-3,5-difluorophenyl)-N-(1,8-naphthyridin-2-yl)hept-6-ynamide [ No CAS ]
(Z)-7-(4-((2,6-difluoro-4-(6-(3-(pyridin-2-yl)ureido)hex-1-yn-1-yl)phenyl)diazenyl)-3,5-difluorophenyl)-N-(1,8-naphthyridin-2-yl)hept-6-ynamide [ No CAS ]